Search research articles
Contact Us
Filters
Showing results (61-70 of 171) with videos related to
Page
of 18
Sort By:
Journal of Clinical Medicine
|
May 28, 2022
Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing
Francesca Prignano, Alexandra M G Brunasso, Gabriella Fabbrocini, et al.
Physical Review Letters
|
September 26, 2012
Measurement of the velocity of neutrinos from the CNGS beam with the large volume detector
N Yu Agafonova, M Aglietta, P Antonioli, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 6, 2020
Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors
Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|
November 15, 2012
Mycosis fungoides: disease evolution of the "lion queen" revisited
P Quaglino, N Pimpinelli, E Berti, et al.
Journal of Clinical Medicine
|
January 11, 2024
Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis
Francesca Prignano, Giuseppe Argenziano, Federico Bardazzi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 26, 2024
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study
C Bonifati, S Lembo, A G Richetta, et al.
The Journal of Dermatological Treatment
|
February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Dermatology and Therapy
|
April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical, Cosmetic and Investigational Dermatology
|
December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
Filomena Russo, Marco Galluzzo, Luca Stingeni, et al.
The Journal of Dermatological Treatment
|
May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 171) with videos related to
Sort By:
Page
of 18
Journal of Clinical Medicine
|
May 28, 2022
Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing
Francesca Prignano, Alexandra M G Brunasso, Gabriella Fabbrocini, et al.
Physical Review Letters
|
September 26, 2012
Measurement of the velocity of neutrinos from the CNGS beam with the large volume detector
N Yu Agafonova, M Aglietta, P Antonioli, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 6, 2020
Analysis of Sentinel Node Biopsy and Clinicopathologic Features as Prognostic Factors in Patients With Atypical Melanocytic Tumors
Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|
November 15, 2012
Mycosis fungoides: disease evolution of the "lion queen" revisited
P Quaglino, N Pimpinelli, E Berti, et al.
Journal of Clinical Medicine
|
January 11, 2024
Understanding Barriers Impacting upon Patient Wellbeing: A Nationwide Italian Survey and Expert Opinion of Dermatologists Treating Patients with Moderate-to-Severe Psoriasis
Francesca Prignano, Giuseppe Argenziano, Federico Bardazzi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 26, 2024
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study
C Bonifati, S Lembo, A G Richetta, et al.
The Journal of Dermatological Treatment
|
February 6, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study
Claudio Bonifati, Giuseppe Argenziano, Serena Lembo, et al.
Dermatology and Therapy
|
April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Clinical, Cosmetic and Investigational Dermatology
|
December 18, 2023
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
Filomena Russo, Marco Galluzzo, Luca Stingeni, et al.
The Journal of Dermatological Treatment
|
May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Page
of 18